Hereditary angioedema patients would prefer newer-generation oral prophylaxis

References

• Nzeako UC, Frigas E, Tremaine WJ. Hereditary angioedema: a broad review for clinicians. Arch Intern Med. 2001;161(20):2417–2429.
   Google Scholar
• U.S. National Libray of Medicine. [cited 2020 Feb 5]. Available from: https://ghr.nlm.nih.gov/condition/hereditary-angioedema#statistics.
   Google Scholar
• Zilberberg MD, Nathanson BH, Jacobsen T, et al. Descriptive epidemiology of hereditary angioedema emergency department visits in the United States, 2006–2007. Allergy Asthma Proc. 2011;32(5):390–394.
   PubMed Web of Science ®Google Scholar
• Zilberberg MD, Jacobsen T, Tillotson G. The burden of hospitalizations and emergency department visits with hereditary angioedema and angioedema in the United States, 2007. Allergy Asthma Proc. 2010;31(6):511–519.
   PubMed Web of Science ®Google Scholar
• The voice of the patient: hereditary angioedema – report of the U.S. Food and Drug Administration patient-focused drug development initiative public meeting September 2017. Center for Biologics Evaluation and Research (CBER) and U.S. Food and Drug Administration (FDA); 2018.
   Google Scholar
• Longhurst H, Bygum A. The humanistic, societal, and pharmaco-economic burden of angioedema. Clin Rev Allergy Immunol. 2016;51(2):230–239.
   PubMed Web of Science ®Google Scholar
• Lumry WR, Castaldo AJ, Vernon MK, et al. The humanistic burden of hereditary angioedema: impact on health-related quality of life, productivity, and depression. Allergy Asthma Proc. 2010;31(5):407–414.
   PubMed Web of Science ®Google Scholar
• Toscani M, Riedl M. Meeting the challenges and burdens associated with hereditary angioedema. Manag Care. 2011;20(9):44–51.
   PubMedGoogle Scholar
• Wilson DA, Bork K, Shea EP, et al. Economic costs associated with acute attacks and long-term management of hereditary angioedema. Ann Allergy Asthma Immunol. 2010;104(4):314–320.
   PubMed Web of Science ®Google Scholar
• Maurer M, Magerl M, Ansotegui I, et al. The international WAO/EAACI guideline for the management of hereditary angioedema-The 2017 revision and update. Allergy. 2018;73(8):1575–1596.
   PubMed Web of Science ®Google Scholar
• Gelfand JA, Sherins RJ, Alling DW, et al. Treatment of hereditary angioedema with danazol. Reversal of clinical and biochemical abnormalities. N Engl J Med. 1976;295(26):1444–1448.
   PubMed Web of Science ®Google Scholar
• Siles R. Hereditary angioedema: Cleveland Clinic Center for continuing education; 2017 [cited 2020 Dec 4]. Available from: https://www.clevelandclinicmeded.com/medicalpubs/diseasemanagement/allergy/hereditary-angioedema/#bib12.
   Google Scholar
• Banerji A, Li Y, Busse P, et al. Hereditary angioedema from the patient's perspective: a follow-up patient survey. Allergy Asthma Proc. 2018;39(3):212–223.
   PubMed Web of Science ®Google Scholar
• Visser LA, Louapre C, Uyl-de Groot CA, et al. Patient needs and preferences in relapsing-remitting multiple sclerosis: a systematic review. Mult Scler Relat Disord. 2020;39:101929–101929.
   PubMed Web of Science ®Google Scholar
• Hincapie AL, Penm J, Burns CF. Factors associated with patient preferences for disease-modifying therapies in multiple sclerosis. J Manag Care Spec Pharm. 2017;23(8):822–830.
   PubMed Web of Science ®Google Scholar
• Gelhorn HL, Balantac Z, Ambrose CS, et al. Patient and physician preferences for attributes of biologic medications for severe asthma. PPA. 2019;13:1253–1268.
   Google Scholar
• Schaarschmidt M-L, Schmieder A, Umar N, et al. Patient preferences for psoriasis treatments: process characteristics can outweigh outcome attributes. Arch Dermatol. 2011;147(11):1285–1294.
   PubMedGoogle Scholar
• Mansfield C, Thomas N, Gebben D, et al. Preferences for multiple sclerosis treatments: using a discrete-choice experiment to examine differences across subgroups of US patients. Int J MS Care. 2017;19(4):172–183.
   PubMedGoogle Scholar
• Ciruelos EM, Díaz MN, Isla MD, et al. Patient preference for oral chemotherapy in the treatment of metastatic breast and lung cancer. Eur J Cancer Care (Engl). 2019;28(6):e13164.
   PubMed Web of Science ®Google Scholar
• Chiba T, Hiraoka A, Mikami S, et al. Japanese patient preferences regarding intermediate to advanced hepatocellular carcinoma treatments. Patient Prefer Adherence. 2019;13:637–647.
   PubMed Web of Science ®Google Scholar
• Eek D, Krohe M, Mazar I, et al. Patient-reported preferences for oral versus intravenous administration for the treatment of cancer: a review of the literature. Patient Prefer Adherence. 2016;10:1609–1621.
   PubMed Web of Science ®Google Scholar
• Twelves C, Gollins S, Grieve R, et al. A randomised cross-over trial comparing patient preference for oral capecitabine and 5-fluorouracil/leucovorin regimens in patients with advanced colorectal cancer. Ann Oncol. 2006;17(2):239–245.
   PubMed Web of Science ®Google Scholar
• Borner MM, Schoffski P, de Wit R, et al. Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer. Eur J Cancer. 2002;38(3):349–358.
   PubMed Web of Science ®Google Scholar
• Liu G, Franssen E, Fitch MI, et al. Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol. 1997;15(1):110–115.
   PubMed Web of Science ®Google Scholar
• Boeri M, Myers K, Ervin C, et al. Patient and physician preferences for ulcerative colitis treatments in the United States. Clin Exp Gastroenterol. 2019;12:263–278.
   PubMed Web of Science ®Google Scholar
• Ghazi A, Grant JA. Hereditary angioedema: epidemiology, management, and role of icatibant. Biologics. 2013;7:103–113.
   PubMedGoogle Scholar
• Riedl MA, Banerji A, Busse PJ, et al. Patient satisfaction and experience with intravenously administered C1-inhibitor concentrates in the United States. Ann Allergy Asthma Immunol. 2017;119(1):59–64.
   PubMed Web of Science ®Google Scholar
• Jose J, Lehman EB, Craig T. Evaluating satisfaction of patients with hereditary angioedema with their past and present treatments: implications for future therapies. Allergy Asthma Proc. 2018;39(1):74–80.
   PubMed Web of Science ®Google Scholar
• Lumry WR, Miller DP, Newcomer S, et al. Quality of life in patients with hereditary angioedema receiving therapy for routine prevention of attacks. Allergy Asthma Proc. 2014;35(5):371–376.
   PubMed Web of Science ®Google Scholar
• Bork K, Bygum A, Hardt J. Benefits and risks of danazol in hereditary angioedema: a long-term survey of 118 patients. Ann Allergy Asthma Immunol. 2008;100(2):153–161.
   PubMed Web of Science ®Google Scholar
• Wang A, Fouche A, Craig TJ. Patients perception of self-administrated medication in the treatment of hereditary angioedema. Ann Allergy Asthma Immunol. 2015;115(2):120–125.
   PubMed Web of Science ®Google Scholar
• Tuong L-AC, Olivieri K, Craig TJ. Barriers to self-administered therapy for hereditary angioedema. Allergy Asthma Proc. 2014;35(3):250–254.
   PubMed Web of Science ®Google Scholar